Mark Jit BSc PhD MPH
- Mark Jit's Contacts
- Keppel Street
- WC1E 7HT
- T: +44 (0)20 7927 2852
I work both at LSHTM and also in the Modelling and Economics Unit of Public Health England in Colindale.
I teach postgraduate and professional courses on modelling and economics of infectious diseases, both at LSHTM and elsewhere.
My main research interest is in epidemiological and economic modelling of infectious disease control interventions to support evidence-based public health decision making. In particular, my work has helped inform immunisation policy on a range of vaccines (including HPV, pneumococcal, rotavirus and influenza vaccines) in both developed and developing countries.
- Decision analysis
- Economic evaluation
- Mathematical modelling
Disease and Health Conditions
- Cervical cancer
- Diarrhoeal diseases
- Hospital acquired infection
- Human papillomavirus (HPV)
- Infectious disease
- Pandemic diseases
- Respiratory disease
- Sexually transmitted infection
- East Asia & Pacific (all income levels)
- European Union
- United Kingdom
- Asia-Pacific region
- Cost Effectiveness Analysis
- Health Economics
- Human Papillomavirus
- Infectious Diseases
- Pneumococcal Disease
- Pneumococcal Vaccines
Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich Countries.
Herlihy, N. ; Hutubessy, R. ; Jit, M. ;
Health Aff (Millwood), 2016; 35(2):227-34
Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis.
Wu, J.T. ; Jit, M. ; Zheng, Y. ; Leung, K. ; Xing, W. ; Yang, J. ; Liao, Q. ; Cowling, B.J. ; Yang, B. ; Lau, E.H. ; Takahashi, S. ; Farrar, J.J. ; Grenfell, B.T. ; Leung, G.M. ; Yu, H. ;
PLoS Med, 2016; 13(3):e1001975
The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.
Flasche, S. ; Jit, M. ; Rodríguez-Barraquer, I. ; Coudeville, L. ; Recker, M. ; Koelle, K. ; Milne, G. ; Hladish, T.J. ; Perkins, T.A. ; Cummings, D.A. ; Dorigatti, I. ; Laydon, D.J. ; España, G. ; Kelso, J. ; Longini, I. ; Lourenco, J. ; Pearson, C.A. ; Reiner, R.C. ; Mier-Y-Terán-Romero, L. ; Vannice, K. ; Ferguson, N. ;
PLoS Med, 2016; 13(11):e1002181
Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
Jit, M. ; Brisson, M. ; Laprise, J.F. ; Choi, Y.H. ;
BMJ, 2015; 350:g7584
The broader economic impact of vaccination: reviewing and appraising the strength of evidence.
Jit, M. ; Hutubessy, R. ; Png, M.E. ; Sundaram, N. ; Audimulam, J. ; Salim, S. ; Yoong, J. ;
BMC Med, 2015; 13(1):209
Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Jit, M. ; Brisson, M. ; Portnoy, A. ; Hutubessy, R. ;
Lancet Glob Health, 2014; 2(7):e406-14
Dedicated outreach service for hard to reach patients with tuberculosis in London: observational study and economic evaluation.
Jit, M. ; Stagg, H.R. ; Aldridge, R.W. ; White, P.J. ; Abubakar, I. ; Find and Treat Evaluation Team, . ;
BMJ, 2011; 343:d5376
Economic evaluation of human papillomavirus vaccination in the United Kingdom
Jit, M.; Choi, Y.H.; Edmunds, W.J.
BMJ, 2008; 337:a769
- → View all Mark Jit 's publications